๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pathogenic significance of BSF-2/IL-6 in castleman's disease

โœ Scribed by K. Yoshizaki; T. Matsuda; N. Nishimoto; T. Kuritani; L. Taeho; K. Aozasa; T. Nakahata; H. Tagoh; T. Komori; S. Kishimoto; T. Hirano; T. Kishimoto

Book ID
103625049
Publisher
Elsevier Science
Year
1988
Tongue
English
Weight
89 KB
Volume
10
Category
Article
ISSN
0192-0561

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

IL-2 therapy in Castleman's disease
IL-2 therapy in Castleman's disease
โœ L. Malaguamera; M. Malaguamera; A.M. Todaro; L. Vicari; G. Caci; M.R. Pilastro; ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 184 KB
Elevated levels of tumor necrosis factor
Elevated levels of tumor necrosis factor-beta, gamma-interferon, and IL-6 mRNA in Castleman's disease
โœ Winter, Stuart S.; Howard, Thad A.; Ritchey, A. Kim; Keller, Frank G.; Ware, Rus ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 553 KB

Castleman's disease (CD) is a lymphoproliferative disorder characterized by enlarged hyperplastic lymph nodes. CD may be localized or multifocal, and is often associated with signs and symptoms of generalized inflammation. The systemic manifestations of CD have been previously attributed to an overp